Antipsychotics cardiotoxicity: What's known and what's next

doi:10.5498/wjp.v11.i10.736

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8373)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

448

WORD

132

HTML

6600

Figures (1-2)

163

Tables (1-1)

222

Sum=7565

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

350

Download

458

Sum=808

Oct 19, 2021 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (22)

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Psychiatr. Oct 19, 2021; 11(10): 736-753
Published online Oct 19, 2021. doi: 10.5498/wjp.v11.i10.736

Full Size Figure Download Figure

Figure 1 Summary of clinical manifestations of antipsychotic cardiotoxicity. Typical characteristics for each manifestation are concisely listed in black texts. SGA: Second-generation antipsychotic; FGA: First-generation antipsychotic; TdP: Torsades de pointes.

Citation: Li XQ, Tang XR, Li LL. Antipsychotics cardiotoxicity: What's known and what's next. World J Psychiatr 2021; 11(10): 736-753
URL: https://www.wjgnet.com/2220-3206/full/v11/i10/736.htm
DOI: https://dx.doi.org/10.5498/wjp.v11.i10.736